vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and DNA X, Inc. (SONM). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $16.2M, roughly 1.2× DNA X, Inc.). DNA X, Inc. runs the higher net margin — -29.3% vs -90.7%, a 61.4% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 7.9%).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
NAMS vs SONM — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $16.2M |
| Net Profit | $-17.4M | $-4.8M |
| Gross Margin | — | 11.2% |
| Operating Margin | -186.1% | -24.5% |
| Net Margin | -90.7% | -29.3% |
| Revenue YoY | 740.1% | 7.9% |
| Net Profit YoY | 55.5% | -89.2% |
| EPS (diluted) | $-0.15 | $-4.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $16.2M | ||
| Q2 25 | $19.1M | $11.2M | ||
| Q1 25 | — | $16.7M | ||
| Q4 24 | $12.8M | $15.3M | ||
| Q3 24 | $29.1M | $15.0M | ||
| Q2 24 | — | $11.5M | ||
| Q1 24 | — | $9.1M | ||
| Q4 23 | — | $13.4M |
| Q3 25 | — | $-4.8M | ||
| Q2 25 | $-17.4M | $-7.5M | ||
| Q1 25 | — | $458.0K | ||
| Q4 24 | $-92.2M | $-21.6M | ||
| Q3 24 | $-16.6M | $-2.5M | ||
| Q2 24 | — | $-6.6M | ||
| Q1 24 | — | $-2.9M | ||
| Q4 23 | — | $-1.4M |
| Q3 25 | — | 11.2% | ||
| Q2 25 | — | 7.6% | ||
| Q1 25 | — | 50.0% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 28.2% | ||
| Q2 24 | — | 25.8% | ||
| Q1 24 | — | 31.8% | ||
| Q4 23 | — | 38.1% |
| Q3 25 | — | -24.5% | ||
| Q2 25 | -186.1% | -60.2% | ||
| Q1 25 | — | 3.9% | ||
| Q4 24 | -338.5% | 55.3% | ||
| Q3 24 | -85.9% | -15.8% | ||
| Q2 24 | — | -56.2% | ||
| Q1 24 | — | -29.5% | ||
| Q4 23 | — | -9.3% |
| Q3 25 | — | -29.3% | ||
| Q2 25 | -90.7% | -66.8% | ||
| Q1 25 | — | 2.7% | ||
| Q4 24 | -721.7% | -141.6% | ||
| Q3 24 | -57.2% | -16.7% | ||
| Q2 24 | — | -57.5% | ||
| Q1 24 | — | -31.9% | ||
| Q4 23 | — | -10.1% |
| Q3 25 | — | $-4.83 | ||
| Q2 25 | $-0.15 | $-0.79 | ||
| Q1 25 | — | $0.08 | ||
| Q4 24 | $-0.91 | $-116.99 | ||
| Q3 24 | $-0.18 | $-9.32 | ||
| Q2 24 | — | $-1.41 | ||
| Q1 24 | — | $-0.65 | ||
| Q4 23 | — | $-0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $2.1M |
| Total DebtLower is stronger | — | $5.1M |
| Stockholders' EquityBook value | $778.5M | $-701.0K |
| Total Assets | $815.1M | $40.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $2.1M | ||
| Q2 25 | $739.2M | $2.0M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | $834.2M | $5.3M | ||
| Q3 24 | $422.7M | $9.1M | ||
| Q2 24 | — | $9.6M | ||
| Q1 24 | — | $9.3M | ||
| Q4 23 | — | $9.4M |
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $2.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | — | $-701.0K | ||
| Q2 25 | $778.5M | $-1.3M | ||
| Q1 25 | — | $-1.1M | ||
| Q4 24 | $757.5M | $-5.7M | ||
| Q3 24 | $378.9M | $15.3M | ||
| Q2 24 | — | $17.5M | ||
| Q1 24 | — | $19.8M | ||
| Q4 23 | — | $22.4M |
| Q3 25 | — | $40.2M | ||
| Q2 25 | $815.1M | $36.1M | ||
| Q1 25 | — | $36.0M | ||
| Q4 24 | $864.6M | $39.7M | ||
| Q3 24 | $439.2M | $49.1M | ||
| Q2 24 | — | $45.9M | ||
| Q1 24 | — | $42.4M | ||
| Q4 23 | — | $56.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $-7.0M |
| Free Cash FlowOCF − Capex | $-37.8M | — |
| FCF MarginFCF / Revenue | -197.2% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-7.0M | ||
| Q2 25 | $-37.7M | $-4.9M | ||
| Q1 25 | — | $-9.6M | ||
| Q4 24 | $-37.5M | $-4.5M | ||
| Q3 24 | $-12.5M | $-417.0K | ||
| Q2 24 | — | $-3.4M | ||
| Q1 24 | — | $-168.0K | ||
| Q4 23 | — | $-351.0K |
| Q3 25 | — | — | ||
| Q2 25 | $-37.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-37.5M | $-4.5M | ||
| Q3 24 | $-12.6M | $-554.0K | ||
| Q2 24 | — | $-3.4M | ||
| Q1 24 | — | $-198.0K | ||
| Q4 23 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | -197.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -293.5% | -29.6% | ||
| Q3 24 | -43.2% | -3.7% | ||
| Q2 24 | — | -29.8% | ||
| Q1 24 | — | -2.2% | ||
| Q4 23 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.3% | 0.9% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.3% | ||
| Q4 23 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -20.97× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
